Genprex (NASDAQ:GNPX – Get Free Report) will likely be issuing its resultson Friday, March 27th. Analysts expect the company to announce earnings of ($13.00) per share for the quarter.
Genprex Price Performance
NASDAQ:GNPX opened at $1.92 on Friday. The business’s 50-day moving average is $2.25 and its two-hundred day moving average is $5.37. The firm has a market capitalization of $5.99 million, a PE ratio of -0.07 and a beta of -0.77. Genprex has a 12 month low of $1.71 and a 12 month high of $55.00.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genprex presently has an average rating of “Sell”.
Institutional Investors Weigh In On Genprex
An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP boosted its stake in Genprex (NASDAQ:GNPX – Free Report) by 11.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 340,056 shares of the company’s stock after acquiring an additional 35,661 shares during the period. Susquehanna International Group LLP owned 27.20% of Genprex worth $58,000 at the end of the most recent reporting period. 14.05% of the stock is owned by institutional investors.
Genprex Company Profile
Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.
In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.
Further Reading
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
